Clinical trial
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02606123 is registered in ClinicalTrials.gov with ESSA Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Lead sponsor
- ESSA Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- October 31, 2015
- Completion date
- December 31, 2017
- Enrollment
- 28 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.